Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Abbott Announces New Long-Term Data Evaluating Use of HUMIRA® (Adalimumab) for Patients with Long-Standing Moderate to Severe Rheumatoid Arthritis and for Patients with Early Moderate to Severe RA
Abbott Announces New Long-Term Data Evaluating Use of HUMIRA® (Adalimumab) for Patients with Long-Standing Moderate to Severe Rheumatoid Arthritis and for Patients with Early Moderate to Severe RA
Abbott Announces New Long-Term Data Evaluating Use of HUMIRA® (Adalimumab) for Patients with Long-Standing Moderate to Severe Rheumatoid Arthritis and for Patients with Early Moderate to Severe RA
Submitted by
admin
on November 6, 2011 - 12:45pm
Source:
Yahoo/PR NewsWire
News Tags:
Abbott Laboratories
Humira
rheumatoid arthritis
Headline:
Abbott Announces New Long-Term Data Evaluating Use of HUMIRA® (Adalimumab) for Patients with Long-Standing Moderate to Severe Rheumatoid Arthritis and for Patients with Early Moderate to Severe RA
Do Not Allow Advertisers to Use My Personal information
